3月19日，生物制药公司Akebia Therapeutics（纳斯达克股票代码：AKBA）在盘后交易中股价大幅下跌20.77%，引起了投资者的广泛关注。这一突然的股价下跌主要源于公司宣布的新股发行计划。
据报道，Akebia Therapeutics已开始筹划股票发行，以寻求新的融资。尽管具体的发行规模尚未披露，但这一消息已经引发了市场对潜在股权稀释的担忧。公司已委任Leerink Partners和Piper Sandler作为此次发行的联合账簿管理人。
值得注意的是，在此次暴跌之前，Akebia Therapeutics的股价曾连续四个交易日上涨，累计涨幅高达68%。周三常规交易时段，该股收盘价为2.84美元，上涨11.4%。这种剧烈的股价波动也反映了市场对该公司前景的不确定性。尽管如此，公司上周发布的业绩预期显示，其贫血药物Vafseo在第一季度预计将实现1000万至1100万美元的净产品收入，这可能为公司未来的发展提供一定支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.